Supplementary Table S5: geometric mean concentrations of Anti-Nucleocapsid antibody levels by dose and time (days) since first-dose

group	measure	Days since baseline (since first AZ dose)							
		0	7	14	28	70	98	170	182
Single Dose	n	10	6	13	6	1	0	0	0
	gmc (95% CI), n	33.5 (10.3,109.4) n=10	92.9 (36.3,238.1) n=6	7.5 (1.3,44.3) n=13	32.4 (1.6,664.8) n=6	-	-		
	seroposive %, (95%CI), n	100.0 (72.2-100.0); 10/10	100.0 (61.0-100.0); 6/6	92.3 (66.7-98.6); 12/13	100.0 (61.0-100.0); 6/6	100.0 (20.7-100.0); 1/1	-		
Two Doses	n	74	46	57	50	57	40	3	2
	gmc (95% CI), n	15.1 (7.7,29.4) n=74	15.0 (7.0,32.2) n=46	11.2 (5.1,24.3) n=57	31.4 (18.1,54.5) n=50	14.2 (7.0,29.1) n=57	29.0 (15.4,54.6) n=40	12.6 (0.3,549.7) n=3	99.8 (9.0,1109.8) n=2
	seroposive %, (95%CI), n	93.2 (85.1-97.1); 69/74	95.7 (85.5-98.8); 44/46	82.5 (70.6-90.2); 47/57	96.0 (86.5-98.9); 48/50	91.2 (81.1-96.2); 52/57	95.0 (83.5-98.6); 38/40	100.0 (43.9-100.0); 3/3	100.0 (34.2-100.0); 2/2
Booster	n	17	17	16	18	20	16	14	9
	gmc (95% CI), n	12.2 (2.6,56.1) n=17	58.9 (31.5,110.4) n=17	14.1 (2.9,68.0) n=16	38.6 (15.3,97.3) n=18	40.9 (15.5,107.4) n=20	9.4 (2.5,35.2) n=16	22.0 (6.1,79.7) n=14	53.4 (10.4,274.4) n=9
	seroposive %, (95%CI), n	88.2 (65.7-96.7); 15/17	100.0 (81.6-100.0); 17/17	81.2 (57.0-93.4); 13/16	94.4 (74.2-99.0); 17/18	95.0 (76.4-99.1); 19/20	87.5 (64.0-96.5); 14/16	100.0 (78.5-100.0); 14/14	100.0 (70.1-100.0); 9/9
Overall	n	101	69	86	74	78	56	17	11
	gmc (95% CI), n	15.7 (9.1,27.3) n=101	24.7 (14.2,42.8) n=69	11.0 (5.9,20.5) n=86	33.1 (21.0,52.3) n=74	17.5 (9.7,31.7) n=78	21.0 (11.8,37.6) n=56	19.9 (6.8,58.5) n=17	59.9 (16.5,217.8) n=11
	seroposive %, (95%CI), n	93.1 (86.4-96.6); 94/101	97.1 (90.0-99.2); 67/69	83.7 (74.5-90.0); 72/86	95.9 (88.7-98.6); 71/74	92.3 (84.2-96.4); 72/78	92.9 (83.0-97.2); 52/56	100.0 (81.6-100.0); 17/17	100.0 (74.1-100.0); 11/11

GMC – Geometric Mean Concentration; CI – Confidence Interval